Exploring the Therapeutic Potential and Challenges of Tin Mesoporphyrin (SnMP) in the Treatment of Neonatal Hyperbilirubinemia

Hyperbilirubinemia is a common neonatal condition that manifests itself as elevated levels of bilirubin in the blood and, if left untreated, may lead to severe neurological damage. Existing treatments, such as phototherapy and blood exchange therapy, are usually administered after bilirubin has already reached dangerous levels. Tin mesoporphyrin (SnMP), a potent heme oxygenase (H.O.) inhibitor, presents a preventive approach, potentially reducing bilirubin production before it reaches critical levels. This review evaluates SnMP's synthesis, mechanism of action, and metabolic pathway, emphasizing its effectiveness compared to other H.O. inhibitors such as Zinc protoporphyrin (ZnPP). Contrary to widespread fears, we present clinical findings showing that SnMP phototoxicity does not pose a significant risk in clinical Settings, supporting SnMP as a safer and more effective alternative to current therapies. Our analysis shows that with further research and optimization of its formulation, SnMP can be a breakthrough therapy for effectively and safely preventing severe hyperbilirubinemia.